Trading Report: Today: Burke & Herbert Bank & Trust Co. Sold shares of Gilead Sciences Inc. (GILD)

Today: Burke & Herbert Bank & Trust Co. Sold shares of Gilead Sciences Inc. (GILD)

Burke & Herbert Bank & Trust Co. reduced its stake in Gilead Sciences Inc. (NASDAQ:GILD) by 7.7% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,465 shares of the biopharmaceutical company’s stock after selling 370 shares during the period. Burke & Herbert Bank & Trust Co.’s holdings in Gilead Sciences were worth $372,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. CWM LLC boosted its stake in Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock valued at $247,000 after buying an additional 17 shares during the period. Cypress Wealth Advisors LLC boosted its stake in Gilead Sciences by 1.4% in the first quarter. Cypress Wealth Advisors LLC now owns 3,875 shares of the biopharmaceutical company’s stock valued at $356,000 after buying an additional 54 shares during the period. Carroll Financial Associates Inc. boosted its stake in Gilead Sciences by 1.2% in the second quarter. Carroll Financial Associates Inc. now owns 4,875 shares of the biopharmaceutical company’s stock valued at $406,000 after buying an additional 60 shares during the period. Mountain Pacific Investment Advisers Inc. ID boosted its stake in Gilead Sciences by 2.1% in the second quarter. Mountain Pacific Investment Advisers Inc. ID now owns 3,574 shares of the biopharmaceutical company’s stock valued at $298,000 after buying an additional 74 shares during the period. Finally, iAB Financial Bank boosted its stake in Gilead Sciences by 3.3% in the second quarter. iAB Financial Bank now owns 2,750 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 87 shares during the period. Institutional investors and hedge funds own 77.93% of the company’s stock.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.42% on Friday, hitting $72.75. The company’s stock had a trading volume of 7,359,055 shares. Gilead Sciences Inc. has a one year low of $72.21 and a one year high of $111.11. The firm has a market cap of $96.01 billion, a price-to-earnings ratio of 6.38 and a beta of 1.10. The stock has a 50-day moving average price of $77.93 and a 200 day moving average price of $84.45.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The business earned $7.78 billion during the quarter, compared to the consensus estimate of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business’s revenue was down 5.7% compared to the same quarter last year. During the same quarter last year, the firm earned $3.15 EPS. Equities research analysts predict that Gilead Sciences Inc. will post $11.76 EPS for the current year.

The company also recently declared a quarterly dividend, which was paid on Thursday, September 29th. Stockholders of record on Friday, September 16th were issued a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.58%. Gilead Sciences’s dividend payout ratio is currently 16.56%.

Several equities research analysts have weighed in on the company. Piper Jaffray Cos. set a $108.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, August 21st. Jefferies Group reissued a “hold” rating and issued a $97.00 target price on shares of Gilead Sciences in a research report on Friday, July 15th. Argus lowered Gilead Sciences from a “buy” rating to a “hold” rating and decreased their target price for the stock from $88.00 to $81.00 in a research report on Friday, July 29th. RBC Capital Markets reissued an “outperform” rating and issued a $105.00 target price (down previously from $120.00) on shares of Gilead Sciences in a research report on Tuesday, July 26th. Finally, Barclays PLC reissued an “overweight” rating on shares of Gilead Sciences in a research report on Thursday, July 28th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company. Gilead Sciences currently has a consensus rating of “Buy” and an average target price of $103.78.

In other news, EVP Paul Rutherford Carter sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the completion of the sale, the executive vice president now owns 64,122 shares in the company, valued at approximately $5,117,576.82. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Gregg H. Alton sold 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 22nd. The stock was sold at an average price of $81.84, for a total transaction of $409,200.00. Following the sale, the executive vice president now owns 132,964 shares of the company’s stock, valued at approximately $10,881,773.76. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment